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Abstract
Of the five human KCNQ (Kv7) channels, KCNQ1 with auxiliary subunit KCNE1 mediates the native cardiac IKs current with
mutations causing short and long QT cardiac arrhythmias. KCNQ4 mutations cause deafness. KCNQ2/3 channels form the
native M-current controlling excitability of most neurons, with mutations causing benign neonatal febrile convulsions.
Drosophila contains a single KCNQ (dKCNQ) that appears to serve alone the functions of all the duplicated mammalian
neuronal and cardiac KCNQ channels sharing roughly 50–60% amino acid identity therefore offering a route to investigate
these channels. Current information about the functional properties of dKCNQ is lacking therefore we have investigated
these properties here. Using whole cell patch clamp electrophysiology we compare the biophysical and pharmacological
properties of dKCNQ with the mammalian neuronal and cardiac KCNQ channels expressed in HEK cells. We show that
Drosophila KCNQ (dKCNQ) is a slowly activating and slowly-deactivating K
+ current open at sub-threshold potentials that
has similar properties to neuronal KCNQ2/3 with some features of the cardiac KCNQ1/KCNE1 accompanied by conserved
sensitivity to a number of clinically relevant KCNQ blockers (chromanol 293B, XE991, linopirdine) and opener (zinc
pyrithione). We also investigate the molecular basis of the differential selectivity of KCNQ channels to the opener retigabine
and show a single amino acid substitution (M217W) can confer sensitivity to dKCNQ. We show dKCNQ has similar
electrophysiological and pharmacological properties as the mammalian KCNQ channels, allowing future study of
physiological and pathological roles of KCNQ in Drosophila and whole organism screening for new modulators of KCNQ
channelopathies.
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Introduction
Voltage-gated potassium (Kv) channels form a diverse gene
family with 40 members in humans divided into 12 subfamilies.
Because mutations in over sixty channel genes are already known
to result in human disease, developing viable genetic models to
study individual ion channel functions and channelopathies is of
increasing clinical importance [1,2]. KCNQ channels are a
particular hotspot of genetic diseases reflecting the range of
important physiological roles they mediate. KCNQ1 assembles
with KCNE1 auxiliary subunits in cardiac muscle to produce the
native slowed delayed rectifier current (IKS). Mutations of KCNQ1
cause a number of life threatening diseases, for instance, loss of
function mutations cause the common cardiac arrhythmia Long
QT syndrome associated with increased risk of Torsades des
Pointes arrhythmia and sudden death. Some KCNQ1 loss of
function mutations, result in Jervell and Lange-Nielsen syndrome
which involve cardiac and auditory defects. Conversely, KCNQ1
gain of function mutations result in hastening of the cardiac action
potential repolarization causing Short QT syndrome and atrial
fibrillation. KCNQ1 is a major target of anti-arrhythmic drugs,
with blockers prolonging repolarization hence treating Short QT
syndrome and openers speeding repolarization in Long QT
syndrome [1–4]. Recently KCNQ1 mutations have also been
found to be strongly associated with Type II (adult onset) diabetes
[5,6].
KCNQ2-5 are expressed in the nervous system with KCNQ2
and KCNQ3 heteromultimerising to form the main channel
mediating the M-current (named after its suppression by
muscarinic acetylcholine receptor agonists), a slowly activating
and slowly deactivating potassium (K
+) current open in the voltage
range required for action potential generation therefore determin-
ing neuronal excitability in most neurons. Loss of functions
mutations in either KCNQ2 or KCNQ3 result in a form of
epilepsy called benign neonatal febrile convulsions [7]. KCNQ5 is
highly expressed in hippocampus and cortex and may contribute
to M-current and excitability in these brain regions by hetero-
multimerising with KCNQ3 [8]. KCNQ4 is expressed in the
cochlea and is important for auditory physiology with loss of
function mutations result in autosomal dominant deafness and
age-related hearing impairment [9,10]. M-current inhibitors such
as linopirdine and XE-991 increase excitability and have been
shown to improve learning and memory in some animal models
including those for dementia while neuronal KCNQ channel
specific openers such as retigabine are anticonvulsants and
flupirtine is used clinically as an analgesic [2,11,12]. The
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importance of KCNQ channel expression and function in cells
other than cardiac myocytes and neurons [13].
As opposed to the five KCNQ channels in mammals, Drosophila
has a single KCNQ channel [14] that is expressed broadly in both
the nervous system and heart [15,16] and its genome does not
contain any KCNE genes [14]. Expression of Drosophila KCNQ
(dKCNQ) in Chinese Hamster Ovary (CHO) cells showed that it
encodes a voltage-sensitive K
+ current that activates and
deactivates slowly becoming active in the sub-threshold voltage
range (from about 260 mV) similar to the M-current. It was also
shown that dKCNQ mediates an M-current because it was
suppressed by activation of a muscarinic receptor [15].
dKCNQ has been shown to have a important cardiac function,
which was shown to be age-dependent. dKCNQ levels were shown
to decrease in aging heart in parallel with an increase in incidence
of cardiac arrhythmias and dysfunction. Hearts from young
dKCNQ null flies already have the prolonged contractions and
fibrillations similar to Torsades des Pointes arrhythmias and as
seen in aged flies [16].
In order to study the function of KCNQ channels further and to
help develop a genetic model for KCNQ channelopathies we have
characterised the electrophysiological and pharmacological prop-
erties of Drosophila KCNQ. We perform the first detailed
comparison of dKCNQ to mammalian cardiac and neuronal
KCNQ channels in terms of their electrophysiological properties
and characterise the effect of a range of clinically relevant
pharmacological KCNQ blockers and openers.
Results
dKCNQ current is similar to the neuronal M-current
mediated by KCNQ2/3 channel but has some features of
the cardiac KCNQ1/KCNE1 (IKs) current
The single Drosophila KCNQ channel shows a high level of amino
acid identity with the human KCNQ channels: KCNQ5 (amino
acid identity, 64%), KCNQ4 (61%), KCNQ2 (57%), KCNQ1
(47%) and KCNQ3 (46%). Previous studies have reported both
neuronal and cardiac expression of dKCNQ [15,16], but absence of
KCNE genes in Drosophila [14]. In order to make a detailed
electrophysiological and pharmacological comparison between
dKCNQ and mammalian neuronal KCNQ2/3 and cardiac
KCNQ1/KCNE1 currents, we expressed the respective channels
in Human Embryonic Kidney (HEK) cells, comparison of this
combination of subunits was chosen as these are the subunits
expected in the channel complexes in native Drosophila [14–16],
mammalian neuronal [7,13,17,18] and cardiac [3,4,19] tissue
respectively. Whole cell voltage clamp recordings revealed dKCNQ
(Figure 1B) showed many of the features of the M-current encoded
by mammalian KCNQ2/3 channels (Figure 1A), including
activation in a range likely to be subthreshold for action potential
firing (Figure 1D–E and G–H; Table 1). Conductance-voltage (G-
V) curves show that dKCNQ reaches half maximal activation
around V0.5=24.963.4 mV (n=5) around the value (p.0.05) for
KCNQ2/3 (V0.5=215.361.4 mV, n=5), with the cardiac
KCNQ1/KCNE1 (Figure 1C, F and I; Table 1) current activating
at more depolarized voltages (V0.5=23.967.1 mV, p,0.05, n=4).
The slope factor (Table 1), a measure of the depolarization required
for an e-fold change in conductance is 15.261.9 mV for dKCNQ
which is most similar and not significantly different (p.0.05) to
KCNQ2/3 (10.661.0 mV) but again intermediate in value
between the mammalian neuronal M-current and the cardiac
KCNQ1/KCNE1 current (19.461.2 mV) which also was not
significantly different from the dKCNQ slope factor (p.0.05). The
activation can be described by a sum of two exponentials (Table 1),
with time constants of 78.6615 and 16656685 ms for dKCNQ at
0 mV. The deactivation can be also described by sum of two
exponentials with the time constant of 30.3614.0 ms for the slow
component and 14.864.4 ms for the fast component at 0 mV
(n=5). For KCNQ2/3 the activation can be described by a sum of
two exponentials (Table 1), with time constants of 80.3625 and
254642 ms at 0 mV and a single deactivation time constant of
17.261.2 ms at 0 mV (n=5). While the KCNQ1/KCNE1
activation can be described by a sum of two exponentials with time
constants of 11886180 and 17526578 ms at 0 mV and a single
exponential of 10.061.1 ms at 0 mV for the deactivation curve
(n=4).The dKCNQ fast activation component was significantly
different (p,0.05) to the KCNQ1/KCNE1 fast activation compo-
nent but similar (p.0.05) to the KCNQ2/3 fast activation.
Conversely the dKCNQ slow activation component was signifi-
cantly (p,0.05) different to KCNQ2/3 slow activation component
although more similar (p.0.05) to the KCNQ1/KCNE1 slow
activation component. There was no significant (p.0.05) difference
between the three different deactivation components.
Differential specificity of retigabine and zinc pyrithione
between KCNQ channels
Retigabine is currently in Phase III clinical trials as an anti-
epileptic that specifically activates KCNQ2/3 channels by causing
a hyperpolarized shift in voltage activation, reducing neuronal
hyperexcitability without affecting KCNQ1/KCNE1 and thus
maintaining normal cardiac excitability [17]. A key residue for
retigabine binding and activation of KCNQ2 is a tryptophan (W)
at position 236 (intracellular side of the fifth transmembrane
segment, Figure 2J) [11,20,21]. Substitution of this residue
(W236L) removes retigabine’s shift of the voltage dependence of
KCNQ3 channel activation, conversely a L266W substitution at
the analogous residue in KCNQ1 (Figure 2J) is sufficient to
increase in the maximal apparent Popen, but does not result in a
shift of the activation curve [20]. Addition of 10 mM retigabine
(Figure 2C and F) caused a significant (p,0.05) enhancement of
the current of approximately 35% at 230 mV as well as a
hyperpolarized shift of 224 mV in the activation curve (p,0.05,
Figure 2I) of KCNQ2/3 (V0.5=247.164.5 mV) compared to
control (V0.5=223.662.0 mV, n=6). dKCNQ was completely
insensitive in terms of enhancement of current (p.0.05) at the
same concentration of retigabine (Figure 2A), with no shift in
the I-V (D) or G-V curve (G) after drug application (V0.5=
219.860.7 mV) compared to control (V0.5=221.461.0 mV,
p.0.05, n=5) with no significant change in the slope of the
activation curve either.
In order to further refine the mode of action and specificity of
retigabine on KCNQ subtype biophysics we introduced a W
residue at the analogous residue (M217W) of dKCNQ to the
retigabine binding site in KCNQ2/3 (Figure 2J). In the absence of
drug, the mutation did not change the properties of the channel
for instance the V0.5 of the mutant channel (223.465.7 mV) was
the same as the wild-type channel (221.461.0 mV) and no
change in amplitude of the current was seen for instance at
+30 mV the amplitude of the mutant channel (218.8640.4 pA/
pF) was similar (p.0.05) to the wild-type channel (397.26
89.8 pA/pF). Introduction of the tryptophan was sufficient to
confer retigabine sensitivity to dKCNQ. 10 mM retigabine caused
a robust enhancement of approximately 38% (p,0.0001) of
dKCNQ-M217W current at +30 mV (Figure 2B and E), no shift
(p.0.05) in the activation curve (V0.5=227.565.7 mV), com-
pared to control (V0.5=223.465.7 mV; n=8) and with no
significant change in the slope of the activation curve. Therefore
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the channels, at 230 mV when KCNQ2/3 is enhanced dKCNQ-
M217W is not (p.0.05), while at +30 mV when dKCNQ-
M217W is enhanced KCNQ2/3 is not (p.0.05). In summary we
have shown that a tryptophan at residue 217 is necessary to confer
retigabine sensitivity to dKCNQ, suggesting that this residue is
especially important amongst the residues that have been
implicated mediating the effect of retigabine on KCNQ channels
[21].
A second KCNQ activator, zinc pyrithione is known to
discriminate between channel subtypes, opening KCNQ1,
KCNQ2 homomultimers and KCNQ2/3 heteromultimers, but
Figure 1. The Drosophila KCNQ (dKCNQ) current is most similar to neuronal KCNQ2/3 but shows some features of the cardiac
KCNQ1/KCNE1 current. Representative traces of (A) KCNQ2/3, (B) dKCNQ and (C) KCNQ1/KCNE1 currents. HEK cells were held at 280 mV for
100 ms and then depolarized in 10 mV increments from 280 mV to +30 mV for 1.3 sec for KCNQ2/3 and dKCNQ respectively. Cells expressing
KCNQ1/KCNE1 were depolarized from 280 mV to +40 mV. After 2.5 sec the cells were stepped down to 2120 mV for 125 ms. Current over
capacitance at a given voltage is given for (D) KCNQ2/3, (E) dKCNQ and (F) KCNQ1/KCNE1 currents. G-V curves for (G) KCNQ2/3, (H) dKCNQ and (I)
KCNQ1/KCNE1 currents. dKCNQ n=5, KCNQ2/3 n=5 and KCNQ1/KCNE1 n=4.
doi:10.1371/journal.pone.0023898.g001
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pyrithione caused an increase of dKCNQ current of about 20%
(at +30 mV, p,0.001) with no shift (p.0.05) in its voltage
dependence (V0.5=210.961.2 mV) compared to control (V0.5=
210.362.4 mV, n=5) and no significant change in the slope of
the activation curve (Figure 3). The EC50 of zinc pyrithione on
dKCNQ was 15.562.4 mM( n $5) with a Hill coefficient equal to
4.260.06 indicating a positive cooperative process with binding of
one molecule of zinc pyrithione increasing the binding of
subsequent molecules.
dKCNQ shows conserved inhibition by mammalian KCNQ
channel blockers
Chromanol 293B inhibits the cardiac IKs potassium current and
is specific for KCNQ1/KCNE1 as opposed to KCNQ2 [4]. Three
critical residues (T312, I337 and F340) forming the putative drug-
binding site in the pore and sixth transmembrane domain [4] are
conserved between KCNQ1 and dKCNQ (Figure 4F). Chroma-
nol 293B was found to be effective at blocking dKCNQ at 30 mV
causing an approximately 30% reduction in current (p,0.05,
Figure 4A and C, n=8) and blocking KCNQ1/KCNE1 at 30 mV
causing an approximately 56% decrease in current (p,0.05,
Figure 4B and D, n=4) without causing a change in the activation
curve of the respective channels (Figure S1A–B). The IC50 for
dKCNQ was 13.063.6 mM with a Hill coefficient of 0.760.1
(n$8, Figure 4), similar to IC50 for KCNQ1/KCNE1 of about
6.960.5 mM [4] and suggesting chromanol 293B acts by a non-
cooperative process whereby each molecule bound decreases the
affinity of binding of a subsequent molecule of the drug.
The M-current is known to be blocked by XE991 and
linopirdine in both native neurons and when heterologously
expressed in cells [7,18]. Addition of 10 mM of XE991 similarly
blocked dKCNQ (p,0.05, Figure 5A and C, n=6) and KCNQ2/
3 currents (p,0.05, Figure 5B and D, n=6) reducing their
currents by about 50% at 30 mV, with little change in activation
curves of the channels (Figure S1C–D). The IC50 of XE991 for
dKCNQ was 5.561.1 mM with a Hill coefficient of 1.460.5 (n$8)
which is slightly higher value compared to 0.660.1 mM for
KCNQ2/3 and 0.7560.075 mM for KCNQ1 reported previously
[7]. A Hill coefficient equal to approximately one suggests a non
cooperative process, whereby the affinity of the molecule for a
channel is not dependent on whether or not other molecules are
already bound. Likewise the XE991 analogue, linopirdine, also
showed inhibition of the mammalian M-current by about 40%
and dKCNQ by 30% (p,0.05, Figure S2).
Discussion
In order to study the function of KCNQ channels further and
develop a new genetic model for KCNQ channelopathies we have
characterised for the first time the electrophysiological and
pharmacological properties of dKCNQ in comparison to the
mammalian cardiac and neuronal KCNQ channels in order to
validate such an approach. Whereas the human genome contains
one cardiac (KCNQ1) and four neuronal (KCNQ2-5) channels in
this subfamily [2], Drosophila has a single channel (dKCNQ)
broadly expressed in both the cardiac and nervous system of the fly
fulfilling all the functions of the duplicated mammalian KCNQ
genes, with evolutionarily conserved electrophysiological and
pharmacological features of both the cardiac and neuronal
KCNQ channels. Underlying this functional conservation is a
high degree of molecular conservation between the human
KCNQ channels and the ancestral KCNQ in Drosophila, with
the neuronal KCNQ channels being more related to the dKCNQ
than the cardiac channel. The diversity of KCNQ channels in
mammals has made studying these channels in native tissue
problematic making characterisation of functional consequence of
removal of a given KCNQ channel at the whole animal level
difficult due to genetic redundancy or compensation by the
remaining KCNQ channels. A possible solution to this problem is
to use the power of Drosophila genetics, flies with a complete lack of
any KCNQ channels are adult viable and have been shown to
have key hallmarks of KCNQ channelopathies [16]. We found
that dKCNQ encodes a slowly activating and slowly deactivating
voltage gated K
+ current with activation in the sub-threshold
voltage range (from about 260 mV) similar to the M-current, this
being a key feature allowing these channels to be important
regulators of neuronal excitability and why loss of function
mutations cause a form of epilepsy and are associated with
neuropathic pain [2,13,17,18]. Again this suggests that Drosophila
would be a valid model to understand these neural KCNQ
channelopathies and screen for new modulators. We found that
the electrophysiological properties of dKCNQ are more similar to
the M-current encoded by mammalian KCNQ2/3 but interme-
diate in kinetics, current amplitude and voltage activation between
the neuronal and cardiac channel. The values we report for
dKCNQ are comparable to those of a previous study [15], with
our V0.5 being slightly more negative and our deactivation values
being a little faster. These small differences may result from the
different expression systems (HEK this study as compared to CHO
cells in the previous study) and slightly different solutions used in
each study. The V0.5 (215.361.4 mV) for KCNQ2/3 is very
similar to the value previously reported (217.362.2 mV; [17]).
The V0.5 of 19.461.2 mV for KCNQ1/KCNE1 is however more
positive compared to 212.561.1 obtained previously [17], this
could be due to the fact that the voltage step duration we used may
not have been sufficient for the current to reach the maximal
activation. Overall the dKCNQ properties we have described are
similar to those reported in the study of Wen and colleagues who
showed that dKCNQ like KCNQ2/3 could be suppressed by
muscarinic acetylcholine receptor agonist and hence displays the
hallmark of an M-current [15].
In terms of pharmacology, we show dKCNQ display conserved
sensitivity to the mammalian cardiac and neuronal KCNQ drugs
with the classic M-current blockers such as linopirdine and XE991
being effective in inhibiting dKCNQ. Conversely specific
enhancers of neuronal KCNQ channels such as retigabine are
effective as anticonvulsants by enhancing KCNQ2-5 currents
while not disrupting the cardiac KCNQ1 currents [11,17]. We
found dKCNQ was insensitive to retigabine, like KCNQ1 which
Table 1. Drosophila KCNQ kinetics are intermediate between
those of the mammalian neuronal KCNQ2/3 and cardiac
KCNQ1/KCNE1 current, but are more similar to KCNQ2/3.
KCNQ2/3 dKCNQ KCNQ1/KCNE1
V0.5 (mV) 215.361.4 24.963.4 23.967.1
Slope factor 10.661.0 15.261.9 19.461.2
Activation t (ms)
Fast: 80.3625 78.6615 11886180
Slow: 254642 16656685 17526578
Deactivation t (ms) 17.261.2 14.864.4 10.061.1
30.3614
n5 5 4
doi:10.1371/journal.pone.0023898.t001
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PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e23898Figure 2. Retigabine displays differential specificity between KCNQ channels with sensitivity conferred by substitution of a single
tryptophan residue. (A) Representative traces showing dKCNQ current (black) was insensitive to addition of 10 mM retigabine (grey), no shift in the
I-V (D), G-V curve (G) or change (p.0.05) in slope factor (slope factor with retigabine=18.360.8 mV) compared to control (slope
factor=19.761.2 mV, n=5). The same retigabine concentration causes a robust activation of KCNQ2/3 current trace (C) and I-V curve (F) as well
as significant leftward shift in the activation curve (I) compared to control. Retigabine did not cause a change (p.0.05) in slope factor for KCNQ2/3
(slope factor=12.261.0 mV) compared to control (slope factor=10.360.7 mV, n=6). A single amino acid substitution (M217W) in the fifth
transmembrane segment of dKCNQ confers sensitivity to retigabine resulting in large current activation (B) at more depolarized voltages on the I-V
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therefore introduced this residue into dKCNQ (M217W) and
found this was sufficient to allow retigabine to increase the
dKCNQ current. Substitution of this single residue in dKCNQ
was not however sufficient to confer a hyperpolarizing shift in
voltage activation in the presence of retigabine. The magnitude of
the hyperpolarizing shift caused by retigabine was greatest for
KCNQ3, followed by KCNQ2/3, KCNQ2, KCNQ4 and
KCNQ1-L266W, each resulting in an increase in Popen probability
[17,18]. The non-significant shift (23 mV) of the dKCNQ
activation curve is most similar to the shift (23 mV) seen for
homomeric KCNQ4 [17]. Our data suggest that there are
additional residues required to allow the retigabine induced
hyperpolarizing shift in activation that are not present in dKCNQ
but are present in mammalian neuronal KCNQs. Recently the
retigabine binding site has been redefined highlighting the
Figure 3. The KCNQ activator, Zinc pyrithione enhances dKCNQ current. Representative traces (A), I-V (B) and G-V (C) plots showing 10 mM
zinc pyrithione causes strong activation of dKCNQ compared to control, as has previously been reported for mammalian KCNQ channels [11].
Addition of zinc pyrithione did not change (p.0.05) the slope factor of dKCNQ (slope factor with drug=18.763.9 mV) compared to control (slope
factor=18.163.9 mV, n=5). The activation by zinc pyrithione was reversible. n=5.
doi:10.1371/journal.pone.0023898.g003
curve (E) however no leftward shift in the activation curve (H) is seen with the drug, compared to control. There slope factor with drug (slope
factor=21.867.0 mV), did not change (p.0.05) compared to control (slope factor=19.467.8 mV, n=8). The activation was reversible. J) Alignment
of KCNQ2, KCNQ3, dKCNQ and KCNQ1 amino acid sequences in the region of the S4 and S5 transmembrane segments. The tryptophan known to be
important for retigabine binding [11,17] is denoted by an asterisk. KCNQ2/3 n=6, dKCNQ n=5 and dKCNQ-M217W n=8.
doi:10.1371/journal.pone.0023898.g002
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e23898importance of additional residues for hyperpolarizing shift in
activation of KCNQ channels [21], these could be candidate
residues to confer this sensitivity to dKCNQ.
Activation of K
+channels by chemical openers is generallyrare and
therefore mechanistically revealing. Furthermore, KCNQ openers
have the potential to treat epilepsy, cardiac arrhythmias, neuropathic
pain, anxiety and neurodegenerative diseases [2,11,13,18]. Zinc
pyrithione is another neuronal KCNQ opener that binds at an
independent site to retigabine (therefore, for each KCNQ tetrameric
channel there are four zinc pyrithione and four retigabine binding
sites) with coapplication of the drugs allowing rescue of KCNQ2
benign familial neonatal convulsions causing mutations to wildtype
[11]. We therefore tested if dKCNQ was sensitive to activation byzinc
pyrithione and found the drug gave an enhancement of current with a
H i l lc o e f f i c i e n tt h a ts u g g e s t st h a tt h ef i r s tm o l e c u l eb o u n dt ot h e
channel promotes the binding of subsequent molecules to the channel
complex, this is similar to values for KCNQ2 suggesting that their
binding sites may show some conservation [11]. Further work will be
required to determine these conserved residues, however we have
demonstrated that dKCNQ can be used to study subtype specificity of
KCNQ chemical modulators and that Drosophila has the potential to
be used to screen and characterise the function of new neuronal
KCNQ enhancers and blockers.
KCNQ has also been shown to have conserved cardiac
functions between Drosophila and human [16], we therefore wished
to see if potential class III antiarrhythmics that inhibit cardiac IKs
potassium channels were also effective on dKCNQ currents. We
found that chromanol 293B [4] similarly blocked both the
mammalian cardiac and Drosophila KCNQ with the three critical
residues (KCNQ1 T312, I337 and F340) forming the putative
drug-binding site in the pore and sixth transmembrane domain
being conserved in both channels. Previous work has shown that
chromanol 293B specifically acts on the native slow delayed
current (IKs) mediated by KCNQ1/KCNE1 subunits but has little
effect on homomeric KCNQ1 or on KCNQ2-5 (4). The
homomeric KCNQ1 channel mediates a rapidly activating and
slowly deactivating K
+ current which is not a native current
normally found in cardiac tissue [19].
The mechanisms underlying development and function of the
heart are basically conserved between Drosophila and human with
KCNQ channels having a central and conserved role in the hearts
of both types of animal [16]. Because Drosophila has a separate
means to distribute oxygen via its tracheal system, genetic or drug
manipulations that cause extreme cardiac pathology can be
characterised which would be immediately lethal in mammalian
systems [22]. We have gone on to show that dKCNQ electrophys-
iology and pharmacology also show conservation with human
KCNQ1/KCNE1 channels. This allows Drosophila to be used as a
valid model to screen and understand mechanism of actions of new
KCNQ based therapies for cardiac channelopathies. One impor-
tant advantage of such a model is it will be possible to high-
throughput screen for either new chemical or genetic modulators of
KCNQ pathological states at the whole organism level allowing the
signalling networks underlying cardiac arrhythmias or epilepsy [22–
24], to be interrogated byDrosophilamolecular genetics. In summary
the ancestral KCNQ channel in Drosophila displays conserved
electrophysiology and accompanying pharmacology intermediate
between the cardiac and neuronalKCNQallowingittoserve all the
functions of the duplicated mammalian KCNQ channels expressed
in the cardiac and nervous systems.
Materials and Methods
Sequence comparison
Genomic database searches were performed with Drosophila
melanogaster RE26469 full-length KCNQ cDNA (FlyBase ID
FBcl0234919) using the WU-BLAST (basic local alignment search
tool) server at EMBL-EBI (European Bioinformatics Institute).
DNA reagents
Drosophila KCNQ RE26469 cDNA (Flybase FBgn0033494,
vector: pIRES2-EGFP; [15]), rat KCNQ2 cDNA (GenBank
accession no: AAC36722; vector: pcDNA3.1; [25]), rat KCNQ3
cDNA (GenBank accession number AC79846; vector: pcDNA3.1;
[25]) and human KCNQ1 cDNA co-expressed with KCNE1 cDNA
(accession no: AF000571; vector: pIRES1-CD8; [3]) were used for
all electrophysiological and pharmacological studies. The Drosoph-
ila KCNQ point mutant was made by site-directed mutagenesis
(QuickChange, Stratagene) and was verified by sequencing.
Cell culture
cDNA were expressed in HEK (ECACC, Salisbury, UK) cells for
electrophysiological studies [25]. Cells were dissociated for propa-
gation with PBS-based solution containing EDTA and kept at 37uC
on Dulbecco’s modified eagle medium supplemented with 10% fetal
calf serum and 0.1% penicillin/streptomycin (Invitrogen). The cells
were plated onto 35 mm dishes 48 hours before transfection for
electrophysiological studies. Transfection of cells was made with
polyethylenimine (PEI, Johnson Matthey) by adding cDNA channel
plasmids (1 mgd K C N Q ,1mg KCNQ2 and KCNQ3 in a ratio 1:1,
1 mgK C N Q 1a n d2mg KCNE1 in a ratio 1:2) and coexpressing a
plasmid containing green fluorescent protein (GFP)c D N Ai nr a t i o1 : 1 .
GFP positive cells were selected for subsequent electrophysiological
recordings 12–24 hours of transfection.
Electrophysiology and pharmacology
Whole-cell voltage-clamp recordings were made from single,
uncoupled cells at room temperature using an Axopatch 200A
amplifier (Axon Instruments). Data was acquired using PulseFit
and Pulse software (HEKA Elektonik). Fire-polished electrodes (3–
4M V) were pulled from borosilicate glass and containing the
following for the retigabine studies (in mM): 140 KCl, 0.5 MgCl2,
2 CaCl2, 5 EGTA, and 10 HEPES, at pH 7.2 with KOH. This
gave an internal solution containing 100 nM free Ca
2+. The
external bathing solution was constantly perfused and contained
(in mM): 145 NaCl, 5 KCl, 2 MgCl2, 2 CaCl2, 10 HEPES at
pH 7.2 with KOH, and 310–320 mOsmol. The previous solutions
were adapted from the work on dKCNQ channels in CHO cells
[15]. During the course of the study, we started to use solutions
especially adapted for recording KCNQ currents expressed in HEK
cells [25] this improved the quality of our recordings. However, the
difference in amount of ions present in the two sets of solutions gave a
Figure 4. Chromanol 293B show conserved inhibition of Drosophila and mammalian KCNQ1/KCNE1 channels. Representative traces
showing dKCNQ (A) current (black) was sensitive to block by 10 mM chromanol 293B (grey), this is also reflected in the downward shift of the I-V curve
(C). Traces (B) and I-V curves (D) showing KCNQ1/KCNE1 was sensitive to block by 10 mM chromanol 293B. (E) Dose response curve for chromanol
293B effect on dKCNQ current. The block was reversible. F) Alignment of KCNQ1, dKCNQ, KCNQ2 and KCNQ3 channels protein sequence in the region
of the pore loop and S6 transmembrane segment. The important residues for the chromanol 293B binding site are marked by asterisks [4]. dKCNQ
n=8 and KCNQ1/KCNE1 n=4.
doi:10.1371/journal.pone.0023898.g004
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current (black) was sensitive to block by 10 mM XE991 (grey), this is also reflected in the downward shift of the I-V curve (C). Traces (B) and I-V curves
(D) showing KCNQ2/3 was sensitive to block by 10 mM XE991. The block was reversible. (E) Dose response curve for XE991 effect on dKCNQ current.
dKCNQ n=6 and KCNQ2/KCNQ3 n=6.
doi:10.1371/journal.pone.0023898.g005
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experiments the following internal solution was used (in mM): 130 K
aspartate, 0.1 EGTA, 5 HEPES (Na), 3 NaOH, 1.5 MgCl2,2 0K C l ,
6.19 CaCl2 (calculated free [Ca
2+]=80 nM), 1.5 NaATP at pH 7.2
with NaCl, the osmolarity was approximately 305 mOsm. The
external solution bath was composed of (mM): 144 NaCl, 2.5 KCl,
1.2 MgCl2,2.5CaCl2,1 0HE PE S( a c i d ),1 0D - g l u c o s ea tp H7 . 2w i t h
NaCl, the osmolarity was approximately 315 mOsmol. The liquid
junction potential was calculated as 214 mV using the application
JPCcalc of pClamp software (Axon instruments) and was subtracted
from voltages to give the x-axis values plotted. The currents were
measured after capacitance and series resistance compensation
(.95%), filtered at 1 kHz using an 8-pole Bessel filter (Frequency
Devices), and sampled at 5 kHz using Pulse (HEKA). Recordings
were subjected to a P/4 leak subtraction protocol [26], which
consisted of four preceding hyperpolarizing prepulses to a voltage one
quarterthesizeofthetestpulsethatwastofollowstartingat280 mV
where the currents of interest are inactive. Drugs used in the study,
retigabine, linopridine, XE991 (10,10-bis(4-Pyridinylmethyl)-9(10H)-
anthracenone), chromanol 293B and zinc pyrithione, were obtained
either from Sigma or Tocris. Stock solutions of drugs were made in
water, alcohol, or dimethyl sulfoxide. The concentration of solvents
added to the cells had no effect by itself. Extracellular application of
the drugs was performed in the recordings presented.
To show the effect of drug application at maximum depolariza-
tion, traces were generated using a single pulse protocol where cells
were held at 280 mV for 100 ms, stepped to +30 mV then after
1 s,stepped downto2120 mVfor250 ms.TogenerateI-VandG-
V curves the following multi-step protocol was used, cells were held
at 280 mV for 100 ms, then stepped in increments of 10 mV from
280 mV to +30 mV then after 1.3 s, before stepping down to
2120 mV for 250 ms. KCNQ1/KCNE1 expressing cells which
were depolarized from 280 mV to 30 mV then after 2.5 sec were
stepped down to 2120 mV for 250 ms. In order to construct the
current-voltage (I-V) plots, currents were measured at the end of the
sweep at the maximum of the current for each step. I-V curves were
plotted as normalised currentin pA/pFagainst membrane potential
in mV. The cell capacitance was obtained by nullifying the
capacitive transients in the test pulse. All mean current values are
presented as 6 standard error of the mean (SEM).
Activation curves were calculated from the tail current at
2120 mV at the end of each test pulse. Normalised tail currents
were plotted against voltage to create the activation curve. For the
retigabine and zinc pyrithione enhancers the current amplitude
was measured at each voltage step and normalised to the
maximum tail current amplitude at 30 mV in absence of the
drugs. Activation curves were fit to the Boltzmann equation G/
Gmax=1/{1+exp[(V0.52Vm)/S]}, where Vm is the membrane
voltage, V0.5 is the voltage at half-maximal activation, and S is a
slope factor at Vm=V0.5 [27]. Mean V0.5 values are shown 6
S.E.M. The exponential time course of activation and deactivation
curves were fitted using PulseFit software (HEKA Elektonik). The
activation curve was fitted with double exponentials for all three
channels from the start of the current at the beginning of the pulse
to the point of peak current activation. A double exponential
provided the best fit for the dKCNQ deactivation curve, while a
single exponential gave the best fit of the KCNQ2/3 and KCNQ1
channels. The exponential was fitted after the peak of the current
and at a point at the end of the sweep.
For concentration response relationships data points representing
fractional current remaining (I/Icont) were fit with a variable Hill
coefficient equation of the form: I/Icontrol=A 1+(A22A1)/1+
10
(logEC502[X])nh, where I is the recorded macroscopic current, Icont
the current in control conditions, A1 the minimum fraction of
current remaining, A2 the maximum fraction of current remaining,
EC50 the antagonist/agonist concentrationthat provokes a response
halfway between baseline and maximum, X is the logarithm of
agonist/antagonist concentration and nh the Hill coefficient. Unless
otherwise stated the fitting regime was performed on data from
individual experiments and the fit parameters quoted are of the
mean 6 SEM of the individual fits. The fractional block and the
fractional enhance were calculated with the following equation:
12(Iblocked/Icontrol) and (Ienhanced/Icontrol)21. The curves displayed in the
figures are representative curve fits to the mean data. Data were
analysed using Graphpad Prism with Student’s paired t test.
Currents size and its regulation by drugs were measured from the
amplitude of the activation current recorded at +30 mV. Statistical
analysis was performed making a comparison between drug and
control amplitude with a paired t test.
Supporting Information
Figure S1 The KCNQ blockers: chromanol 293B and
XE991 do not cause a change in voltage activation of the
Drosophila and mammalian KCNQ channels. The V0.5 and
slope factor of activation curves of dKCNQ with chromanol 293B
application (V0.5=27.463.6 mV; slope factor=16.363.2 mV) were
similar (p.0.05) to control (V0.5=25.363.4 mV; slope factor=
15.562.2 mV, n=8). Likewise G-V curves (B) for KCNQ1/KCNE1
with 10 mM chromanol 293B application (V0.5=22.166.8 mV; slope
factor=14.761.9 mV) overlapped with control (V0.5=25.262.5 mV;
slope factor=13.360.6 mV, n=4), with no changes in V0.5 or slope
factor (p.0.05). The activation curve of dKCNQ (C) with XE991
(V0.5=26.861.8 mV and slope factor=14.762.1 mV) was similar to
control (V0.5=26.060.8 mV; slope factor=12.260.5 mV, n=6),
with no changes in V0.5 or slope factor (p.0.05). The KCNQ2/3
activation curve (D) with XE991 gave values for V0.5=
222.061.8 mV and slope factor=11.161.1 mV neither of which
were significantly (p.0.05) shifted compared to control (V0.5=
213.260.5 mV; slope factor=14.361.8 mV, n=6).
(TIF)
Figure S2 The KCNQ blocker: linopirdine shows con-
served inhibition of Drosophila and mammalian KCNQ
channels. Representative traces (A) and I-V curve (C) showing
dKCNQ current (black) is sensitive to block (at 30 mV, p,0.01)
by 10 mM linopirdine (grey), similar inhibition (p,0.05) of
KCNQ2/3 is seen (B and D). Activation curves of dKCNQ
(C) with linopirdine (V0.5=25.763.7 mV and slope factor=
18.563.0 mV) were not different from control (V0.5=210.06
2.0 mV; slope factor=14.561.5 mV, n=5) in terms of V0.5 or
slope factor (p.0.05). The KCNQ2/3 activation curve (D) with
linopirdine gave values for V0.5=218.561.0 mV and slope
factor=8.760.9 mV neither of which were (p.0.05) shifted
compared to control (V0.5=214.061.4 mV; slope factor=
12.861.3 mV, n=5). The block was reversible.
(TIF)
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